TY - JOUR
T1 - Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial
AU - Norris, Robin M.
AU - Rich, Michael W.
AU - Braunwald, Eugene
PY - 1989/8/31
Y1 - 1989/8/31
N2 - To the Editor: For many, the important message of the TIMI Phase II trial (March 9 issue)1 is not so much that the use of a conservative strategy after thrombolysis was vindicated, but that acute myocardial infarction could be treated in 3262 patients, approximately two thirds of whom were in a not-low-risk category, with a six-week mortality rate of under 5 percent. It is, however, difficult to interpret the results of the substudy of intravenous beta-blockade, a treatment that had been investigated extensively during the decade before the introduction of thrombolysis2,3 and that experimental evidence had suggested should be more.
AB - To the Editor: For many, the important message of the TIMI Phase II trial (March 9 issue)1 is not so much that the use of a conservative strategy after thrombolysis was vindicated, but that acute myocardial infarction could be treated in 3262 patients, approximately two thirds of whom were in a not-low-risk category, with a six-week mortality rate of under 5 percent. It is, however, difficult to interpret the results of the substudy of intravenous beta-blockade, a treatment that had been investigated extensively during the decade before the introduction of thrombolysis2,3 and that experimental evidence had suggested should be more.
UR - http://www.scopus.com/inward/record.url?scp=0024373561&partnerID=8YFLogxK
U2 - 10.1056/NEJM198908313210910
DO - 10.1056/NEJM198908313210910
M3 - Letter
C2 - 2503726
AN - SCOPUS:0024373561
SN - 0028-4793
VL - 321
SP - 612
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 9
ER -